(redirected from non-nucleoside reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to non-nucleoside reverse transcriptase inhibitor: NRTI, nucleotide reverse transcriptase inhibitors
NNRTINon-Nucleoside Reverse Transcriptase Inhibitor
References in periodicals archive ?
Also, this regimen, marketed as Eviplera (emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate)) in the EU, was recently granted European regulatory approval for any HIV-infected adult patients without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load = 100,000 HIV-1 RNA copies/mL.
Even though other studies showed that elevations in triglyceride and cholesterol and body shape changes were also seen with the other classes of drugs and not just the protease inhibitors, the field had moved to using a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen as part of first-line therapy.
In addition, patients taking a protease inhibitor were more likely to have hyperglycemia compared to patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI or "non-nuke").
* NNRTIs (non-nucleoside reverse transcriptase inhibitor) target the same reverse transcriptase enzyme, but do not provide false building blocks.
BARCELONA, SPAIN -- An efavirenz-based regimen became the top choice for the initial treatment of HIV infection based on the results of a study that compared a regimen built on a protease inhibitor with a regimen based on a non-nucleoside reverse transcriptase inhibitor.
SUSTIVA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was originally approved in the US in 1998 to treat HIV-1 infected children three years of age or older and weighing at least 10 kg.
New precautions have been added to the labeling for Viramune, a non-nucleoside reverse transcriptase inhibitor (NNRTI or "non-nuke").
This is a very active antiretroviral of the NNRTI class (non-nucleoside reverse transcriptase inhibitor -- the same class as efavirenz, nevirapine, and delavirdine, the three NNRTI drugs currently approved in the U.S.).
Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
For example, Tibotec has 2 drugs in parallel development, a protease inhibitor (PI) with good activity against PI-resistant virus and a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that overcomes viral resistance to other drugs of this type.
It at first restricted entry to persons with viral loads over 10,000 and CD4 counts under 100 -- plus documented treatment failure with at least two protease inhibitors or one PI and one non-nucleoside reverse transcriptase inhibitor (NNRTI).
Full browser ?